摘要
近年来,肺癌在内科药物治疗方面有较大进展,传统化疗、分子靶向药物、靶向药物耐药的后续治疗,以及免疫疗法在晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的综合治疗中扮演着不可替代的角色,但也存在一些不足之处,如化疗及靶向药物的毒副作用和耐药等,5年生存率仍然很低。诸多临床工作者为尽可能的延长晚期NSCLC患者的生存时间、提高患者的生活质量而采用中西医结合的治疗手段,效果明显。该文就晚期非小细胞肺癌的中西医结合药物治疗现状作一综述。
There is a great development in the medical treatment of non -small cell lung cancer recently.Chemotherapy,molecular tar-geted therapy,measures to treat TKI therapy resistant cases,and immune therapy all play irreplaceable roles in the treatment of ad-vanced non -small cell lung cancer.However,there are still some deficiencies including side effects and drug resistance of chemothera-py and targeted therapy as well as low 5 -year survival rate.Therefore,integration of traditional Chinese and western medicine plays an important role in improving the life quality and prolonging patients’life.This paper reviews the status quo of the current integrative treatment of advanced non -small cell lung cancer.
出处
《安徽医药》
CAS
2016年第3期583-585,共3页
Anhui Medical and Pharmaceutical Journal
基金
国家中医药管理局中医肿瘤学重点学科经费资助项目(国中医药发[2009]30号)
关键词
晚期非小细胞肺癌
中西医结合
药物治疗
现状
advanced non -small cell lung cancer
integration of traditional Chinese and western medicine
drug therapy
status quo
作者简介
夏凡，女，硕士研究生
通信作者：李平，男，主任医师，博士生导师，研究方向：中西医结合肿瘤，E-mail：liping64@sina．com
